Moreover, Xu et al. further demonstrated that ccRCC patients undergoing anti-PD-1/PD-L1 therapy exhibited improved survival and response rates when intratumoral TLSs and SFL-TLSs were present 73. The gene discussed is CD274; the disease is nonpapillary renal cell carcinoma.